Having trouble accessing articles? Reset your cache.

Massachusetts compromises on weaker Medicaid drug price disclosures

Responding to a biopharma industry lobbying campaign, the Massachusetts legislature has dialed back drug price and cost disclosure requirements. The requirements are part of provisions in the state budget that

Read the full 303 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE